Literature DB >> 19812066

Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.

Soranun Chantarangsu1, Tim R Cressey, Surakameth Mahasirimongkol, Edmund Capparelli, Yardpiroon Tawon, Nicole Ngo-Giang-Huong, Gonzague Jourdain, Marc Lallemant, Wasun Chantratita.   

Abstract

OBJECTIVES: To investigate the association of single nucleotide polymorphisms (SNPs) with nevirapine concentrations following intra-partum single-dose nevirapine.
METHODS: Plasma and DNA samples were obtained from 330 HIV-infected Thai women who received intra-partum single-dose nevirapine in the PHPT-2 clinical trial to prevent perinatal HIV transmission. Nine SNPs within CYP2B6, CYP3A4 and ABCB1 were genotyped by real-time PCR. Nevirapine plasma concentrations were determined by HPLC and used in a population pharmacokinetic analysis.
RESULTS: Higher nevirapine exposure was observed in women carrying the CYP2B6 516G>T polymorphism, but this did not reach statistical significance (P = 0.054). The TGATC CYP2B6 haplotype (g.3003T, 516G, 785A, g.18492T and g.21563C) was associated with increased nevirapine clearance and lower exposure (P = 0.0029). The median time for nevirapine concentrations to reach 10 ng/mL post-partum (nevirapine IC(50) for HIV-1) was 14 days [interquartile range (IQR, 14-18)] for TGATC homozygotes, 16 days (14-20) for TGATC heterozygotes and 18 days (14-20) for non-TGATC homozygotes (P = 0.020).
CONCLUSIONS: The CYP2B6 516G>T impact on nevirapine concentrations was less pronounced after intra-partum single-dose nevirapine than reported under steady-state conditions, perhaps due to lack of enzyme auto-induction at the time of dosing. Although the TGATC CYP2B6 haplotype may shorten the persistence of nevirapine post-partum, its practical implications for the prevention of HIV transmission or selection of resistance mutations are likely limited.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19812066      PMCID: PMC2775665          DOI: 10.1093/jac/dkp351

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  29 in total

1.  Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.

Authors:  J A H Droste; C P W G M Verweij-Van Wissen; D M Burger
Journal:  Ther Drug Monit       Date:  2003-06       Impact factor: 3.681

2.  Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Authors:  Diane T Holland; Robin DiFrancesco; Judith Stone; Fayez Hamzeh; James D Connor; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Functional characterization of cytochrome P450 2B6 allelic variants.

Authors:  Hideto Jinno; Toshiko Tanaka-Kagawa; Akiko Ohno; Yuko Makino; Erika Matsushima; Nobumitsu Hanioka; Masanori Ando
Journal:  Drug Metab Dispos       Date:  2003-04       Impact factor: 3.922

4.  Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.

Authors:  Marc Lallemant; Gonzague Jourdain; Sophie Le Coeur; Jean Yves Mary; Nicole Ngo-Giang-Huong; Suporn Koetsawang; Siripon Kanshana; Kenneth McIntosh; Vallop Thaineua
Journal:  N Engl J Med       Date:  2004-07-09       Impact factor: 91.245

5.  Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

Authors:  Christoph Wyen; Heidy Hendra; Martin Vogel; Christian Hoffmann; Heribert Knechten; Norbert H Brockmeyer; Johannes R Bogner; Jürgen Rockstroh; Stefan Esser; Hans Jaeger; Thomas Harrer; Stefan Mauss; Jan van Lunzen; Nicole Skoetz; Alexander Jetter; Christiane Groneuer; Gerd Fätkenheuer; Saye H Khoo; Deirdre Egan; David J Back; Andrew Owen
Journal:  J Antimicrob Chemother       Date:  2008-02-14       Impact factor: 5.790

6.  Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression.

Authors:  Jatinder Lamba; Vishal Lamba; Stephen Strom; Raman Venkataramanan; Erin Schuetz
Journal:  Drug Metab Dispos       Date:  2007-10-09       Impact factor: 3.922

7.  CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

Authors:  Akihiko Saitoh; Elizabeth Sarles; Edmund Capparelli; Francesca Aweeka; Andrea Kovacs; Sandra K Burchett; Andrew Wiznia; Sharon Nachman; Terence Fenton; Stephen A Spector
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

8.  Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.

Authors:  Tw Mahungu; Cj Smith; F Turner; D Egan; M Youle; Ma Johnson; S Khoo; Dj Back; A Owen
Journal:  HIV Med       Date:  2009-02-17       Impact factor: 3.180

9.  Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations.

Authors:  Bing-Ying Xu; Li-Ping Guo; Shui-Shan Lee; Qing-Ming Dong; Yi Tan; Hong Yao; Li-Hua Li; Che-Kit Lin; Hsiang-Fu Kung; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

10.  Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.

Authors:  Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Sara Gibbons; Mauro Sciandra; Daniela Colucci; Stefano Bonora; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

View more
  17 in total

1.  Clinical perspectives on human genetic screening to prevent nevirapine toxicity.

Authors:  David W Haas; Piroon Mootsikapun; Kiat Ruxrungtham; Daniel Podzamczer
Journal:  Per Med       Date:  2012-09-01       Impact factor: 2.512

2.  Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.

Authors:  Chonlaphat Sukasem; Tim R Cressey; Pattamawan Prapaithong; Yardpiroon Tawon; Ekawat Pasomsub; Chutatip Srichunrusami; Thawinee Jantararoungtong; Marc Lallement; Wasun Chantratita
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

3.  Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.

Authors:  Kevin C Brown; Mina C Hosseinipour; Janelle M Hoskins; Ranjit K Thirumaran; Hsiao-Chuan Tien; Ralf Weigel; Jean Tauzie; Ida Shumba; Jatinder K Lamba; Erin G Schuetz; Howard L McLeod; Angela D M Kashuba; Amanda H Corbett
Journal:  Pharmacogenomics       Date:  2011-11-23       Impact factor: 2.533

4.  Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.

Authors:  Tim R Cressey; Alice Stek; Edmund Capparelli; Chureeratana Bowonwatanuwong; Sinart Prommas; Pannee Sirivatanapa; Prapap Yuthavisuthi; Chanon Neungton; Yanling Huo; Elizabeth Smith; Brookie M Best; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2012-03-01       Impact factor: 3.731

5.  Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.

Authors:  Patty Fan-Havard; Zhongfa Liu; Monidarin Chou; Yonghua Ling; Aurélie Barrail-Tran; David W Haas; Anne-Marie Taburet
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

6.  Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.

Authors:  Sumonmal Uttayamakul; Sirirat Likanonsakul; Weerawat Manosuthi; Nuanjun Wichukchinda; Thareerat Kalambaheti; Emi E Nakayama; Tatsuo Shioda; Srisin Khusmith
Journal:  AIDS Res Ther       Date:  2010-03-26       Impact factor: 2.250

7.  Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism.

Authors:  C Sukasem; W Manosuthi; N Koomdee; S Santon; T Jantararoungtong; S Prommas; M Chamnanphol; A Puangpetch; S Sungkanuparph
Journal:  Infection       Date:  2013-11-30       Impact factor: 3.553

8.  Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.

Authors:  Saran Vardhanabhuti; Edward P Acosta; Heather J Ribaudo; Patrice Severe; Umesh Lalloo; Nagalingeshwaran Kumarasamy; Frank Taulo; Joseph Kabanda; Olola Oneko; Prudence Ive; Pradeep Sambarey; Ellen S Chan; Jane Hitti; Francis Hong; Deborah McMahon; David W Haas
Journal:  J Infect Dis       Date:  2013-05-17       Impact factor: 5.226

9.  Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.

Authors:  Julie Bertrand; Monidarin Chou; Danielle M Richardson; Céline Verstuyft; Paul D Leger; France Mentré; Anne-Marie Taburet; David W Haas
Journal:  Pharmacogenet Genomics       Date:  2012-12       Impact factor: 2.089

10.  Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.

Authors:  Suzana Mustafa; Wan Nazirah Wan Yusuf; Jean Baptiste Woillard; Tan Soo Choon; Norul Badriah Hassan
Journal:  Eur J Clin Pharmacol       Date:  2016-03-30       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.